67 related articles for article (PubMed ID: 7702421)
1. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
Le Pen C; Lévy E; Bonte J
Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
[TBL] [Abstract][Full Text] [Related]
2. [Cost effectiveness of captopril after myocardial infarct; comment].
Szucs T; Berger K; Schulte-Hillen J; Kleber FX
Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
4. Long-term mortality in patients with myocardial infarction: impact of early treatment with captopril for 4 weeks.
Liu L;
Chin Med J (Engl); 2001 Feb; 114(2):115-8. PubMed ID: 11780187
[TBL] [Abstract][Full Text] [Related]
5. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy:a cost-benefit approach].
Le Pen C; Petitjean P; Lévy P; Hannedouche T
Nephrologie; 1996; 17(6):321-6. PubMed ID: 8975150
[TBL] [Abstract][Full Text] [Related]
9. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
Pfeffer MA
Herz; 1993 Dec; 18 Suppl 1():430-5. PubMed ID: 8125423
[TBL] [Abstract][Full Text] [Related]
10. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
[TBL] [Abstract][Full Text] [Related]
12. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
Chin Med J (Engl); 1997 Nov; 110(11):834-8. PubMed ID: 9772413
[TBL] [Abstract][Full Text] [Related]
13. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
de Pouvourville G; Solesse A; Beillat M
Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD; Goedde M; Berger K; Kiowski W
Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
18. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.
Jose P; Skali H; Anavekar N; Tomson C; Krumholz HM; Rouleau JL; Moye L; Pfeffer MA; Solomon SD
J Am Soc Nephrol; 2006 Oct; 17(10):2886-91. PubMed ID: 16928807
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
20. Postmyocardial infarction patients: experience from the SAVE trial.
Connors KF; Lamas GA
Am J Crit Care; 1995 Jan; 4(1):23-8. PubMed ID: 7894551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]